S449
Clinical - Gynaecological
ESTRO 2026
Digital Poster 2350
recurrence-free survival rates (LRFS-NRFS) and metastases disease free survical (MDFS) were investigated.Adverse events were evaluated according to CTCAE v.5.0. EORTC QLQ-C30 and EORTC QLQ-Cx24, EORTC QLQ- SH22, FSFI (Spanish version), and FSM-2 (Spanish version) questionnaires were used to evaluate global QoL and SH. Statistical analysis: Kaplan-Meier method, Logrank test and Chi-square test. Results: LACC: 3-year OS, DFS, LRFS and NRFS were 87.6%, 93%, 98% and 93%, respectively. Three-year MDFS was 85.5%. Three-year G2-3 proctitis-free-survival and G2-3 rectal- bleeding-free-survival were 85.4% and 86.6%, respectively. In relation to vaginal side effects, vaginal atrophy was detected in 23p (32%), telangiectasia: 17p (26%) and partial vaginal cleisis: 17p (29%). The EORTC QLQ- C30 results indicated a good QoL with functional scores above 90 %, symptom scores below 15% except fatigue (21%) and insomnia (30%); the global health score was 80%. Regarding SH, Cx24 symptom scales showed sexual-enjoyment of 75% but menopausal-symptoms of 31%. EORTC SH22 questionnaire indicated 41.2% sexual activity, but sexual satisfaction: 40%: See Figure- 2.ESCC: 5-year OS, and LRFS were 83.5%, and 96.2%, respectively. Three-year G2-3 proctitis- free-survival and G2-3 rectal-bleeding-free- survival were 85% and 80%, respectively. No G2-3 vaginal stenosis was observed. The EORTC QLQ-C30 results indicated a good QoL with functional scores above 80 %, symptom scores below 20% except fatigue (18%) and insomnia (17%); the global health score was 74%. Regarding SH, Cx24 symptom scales showed sexual-enjoyment less than 20%. EORTC SH22 questionnaire indicated 35% sexual activity, sexual satisfaction: 20%, Vaginal dryness (79.1%) and Sexual pain (39.9%). The FSFI results showed low rates of sexual feelings in ESCC (7.56) compared to LACC (17); and FSM-2 which evaluates the sexual response of women, showed low rates in ESCC (7.6) compared to LACC (18.8).
QUALITY OF LIFE AND SEXUAL HEALTH cervical cancer: early stages and locally advanced Sofia Cordoba Largo, Beatriz Gil Haro, Arancha Gallego Barranco, Francisco Javier Martínez Paredes, Irene Ávila Gómez, Raquel Benlloch Rodríguez, Cristina de la Fuente Alonso, Sofía Santana Jiménez, Marta López Valcárcel, María Hernandez Miguel, Irma Zapata Paz, Joaquín Velasco Jiménez, María Isabel García Berrocal, Jesús Romero Fernández Radiation Oncology, Puerta de Hierro, University Hospital, Madrid, Spain Purpose/Objective: To assess clinical outcomes, side effects, Quality of Life (QoL) and sexual health (SH) in patients diagnosed cervical cancer (CC), both locally advanced cervical cancer (LACC) treated with chemoradiation (CRT) and image-guide-brachytherapy (IGBT-MRI), and early stage (ESCC) treated with adjuvant radiotherapy. Material/Methods: We evaluated 61p with LACC and 27p with ESCC (Figure-1 show patients characteristics). All LACC-patients were treated with CRT and 3D-based intracavitary/interstitial IGBT. ESCC were treated with adjuvant radiotherapy (IMRT-3DRT) or CRT; in selected cases with positive or proximal vaginal margin, patients were treated with 3D-based planning intracavitary brachytherapy.
Overall survival (OS), local and/or regional
Made with FlippingBook - Share PDF online